辐射防护药物研究最新进展

Recent advances in radioprotective agents

电离辐射损伤不仅是一个公众健康问题，同时也是一个国家安全问题。如何获得治疗效果优良、安全性高和不良反应小的辐射防护药物一直是科学家努力研究的目标。近年来，伴随着分子生物学、免疫学等学科的发展，辐射防护药物的研究也取得了较大的突破。目前，诸如5-雄烯二醇（5-AED）、CBLB502、Ex—RAD和HemaMax等药物已获得美国食品药品监督管理局的批准进入临床试验；而新发现的具有潜在价值的LY294002和17-DMAG等药物也正处于研发之中。笔者基于近年来辐射防护领域国外相关刊物和专利的最新发现和进展进行综述。重点放在近几年来出现的药物新进展以及这一时间内治疗急性放射综合征的抗辐射新药上。

Ionizing radiation damage is not only a public health problem but is also a national security issue. Excellent treatment effect, high safety, and small side effects of radioprotective agents have been the goal of scientists attempting to study this concern. In recent years, research on radioprotective agents, along with the development of molecular biology, immunology, and other disciplines, has reached an advanced breakthrough. At present, drugs such as 5-androstenediol （5-AED）, CBLB502, Ex-RAD, and HemaMax have been approved by the US Food and Drug Administration for clinical trials, and newly discovered drugs such as LY294002 and 17-DMAG are under development. This paper is based on the recent discoveries and progress of foreign-related publications and patents in the field of radiation protection. New advances in drugs, as well as anti-radiation drugs for acute radiation syndrome, have been the focus of recent studies.